IceCure Medical Ltd. (NASDAQ:ICCM) Given Consensus Rating of “Hold” by Brokerages

Shares of IceCure Medical Ltd. (NASDAQ:ICCM) have been given an average rating of “Hold” by the five ratings firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $52.50.

ICCM has been the topic of a number of research analyst reports. Maxim Group dropped their target price on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday. Zacks Research cut shares of IceCure Medical from a “hold” rating to a “strong sell” rating in a report on Friday, August 14th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research note on Friday, July 17th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Jane Street Group LLC purchased a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 109,638 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned 0.16% of IceCure Medical as of its most recent filing with the SEC. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

IceCure Medical Price Performance

NASDAQ ICCM opened at $2.23 on Friday. The business’s fifty day moving average is $3.24 and its 200-day moving average is $8.14. The stock has a market capitalization of $7.64 million, a price-to-earnings ratio of -0.26 and a beta of 0.45. IceCure Medical has a one year low of $2.12 and a one year high of $42.00.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings results on Tuesday, June 30th. The company reported ($1.60) earnings per share for the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 174.26%. The company had revenue of $0.91 million for the quarter. Research analysts expect that IceCure Medical will post -4.61 EPS for the current fiscal year.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.